Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Operating Leases (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Operating Leases for 5 consecutive years, with $16.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 16.08% to $16.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.6 million, a 16.08% decrease, with the full-year FY2024 number at $19.0 million, up 64.63% from a year prior.
  • Operating Leases was $16.6 million for Q3 2025 at 4D Molecular Therapeutics, down from $17.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $19.7 million in Q3 2024 to a low of $10.5 million in Q2 2024.
  • A 5-year average of $14.6 million and a median of $14.2 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: fell 16.5% in 2024, then surged 65.93% in 2025.
  • 4D Molecular Therapeutics' Operating Leases stood at $15.2 million in 2021, then fell by 11.49% to $13.5 million in 2022, then decreased by 14.46% to $11.5 million in 2023, then surged by 64.63% to $19.0 million in 2024, then fell by 12.66% to $16.6 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Operating Leases are $16.6 million (Q3 2025), $17.4 million (Q2 2025), and $18.2 million (Q1 2025).